RxDoctor Payments Data

Salman Malik, MD

Neurology · Liberty, MONPI 1497794499

Payments from drug & device makers

$3,816in general payments, 2019–2025

Across 223 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$452
  • Biogen$335
  • AbbVie$334
  • Novartis$302
  • Lilly USA, LLC$276
  • Sanofi$155
  • plus $2K from 40 others

What the payments were for

  • Speaking & faculty fees$481%
  • Food & beverage$3,75698%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,816 in reported general payments places this provider in the 60th percentile of 381 neurology providers in Missouri.

See all neurology providers in Missouri

Medicare billing

Part B allowed, 2024
$175,251
Medicare patients
800
Services billed
2,557

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine12$203,884
IngrezzaValbenazine Tosylate11$102,899
Tetrabenazine13$88,838
NuplazidPimavanserin Tartrate15$65,093
BriviactBrivaracetam26$40,606
AptiomEslicarbazepine Acetate12$28,181
Memantine Hcl863$25,729
Nurtec OdtRimegepant Sulfate17$16,839
Aimovig AutoinjectorErenumab-Aooe22$16,526
NamzaricMemantine Hcl/Donepezil Hcl14$11,380
Gabapentin485$9,752
Levetiracetam277$9,601
Emgality PenGalcanezumab-Gnlm12$7,942
Carbidopa-LevodopaCarbidopa/Levodopa317$7,417
Primidone192$5,286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$100$203,88412 claims
Neurocrine Biosciences, Inc.Ingrezza$148$102,89911 claims
Acadia Pharmaceuticals IncNuplazid$63$65,09315 claims
UCB, Inc.Briviact$452$40,60626 claims
Sunovion Pharmaceuticals Inc.Aptiom$44$28,18112 claims
PfizerNurtec Odt$44$16,83917 claims
AbbVieNamzaric$334$11,38014 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$56$3,99147 claims
Upsher-smith Laboratories LLCTopiramate$81$3,554290 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 381 neurology providers in Missouri.

Other neurology in Liberty

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →